Literature DB >> 9402356

Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia.

M C Roghmann1, R J McCarter, J Brewrink, A S Cross, J G Morris.   

Abstract

A cohort study was conducted in a cancer center to identify risk factors for bacteremia with vancomycin-resistant enterococci (VRE) in neutropenic cancer patients colonized with VRE. There were 10 patients with VRE bacteremia among 56 colonized with VRE, of whose charts 51 were available for review. One hundred percent of patients with VRE bacteremia (10 of 10) vs. 56% of patients without VRE bacteremia (23 of 41) had acute leukemia (P = .01, Fisher's exact test). Four of the 10 patients with VRE bacteremia had a positive Clostridium difficile toxin assay within 6 days of their first positive VRE blood culture. Both C. difficile infection and antimicrobial (vancomycin and ciprofloxacin) use during VRE colonization were significant risk factors for VRE bacteremia in univariate analysis. When a Cox proportional hazards model was used to account for differences in follow-up time, C. difficile infection was the only statistically significant risk factor (risk ratio, 8.2; P = .007) for VRE bacteremia in VRE-colonized patients with acute leukemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402356     DOI: 10.1086/516112

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period.

Authors:  W E Bischoff; T M Reynolds; G O Hall; R P Wenzel; M B Edmond
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  In vitro activity of linezolid against Clostridium difficile.

Authors:  T Peláez; R Alonso; C Pérez; L Alcalá; O Cuevas; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  [Epidemiology of and preventive measures for multiresistant pathogens].

Authors:  E-B Kruse; M Dettenkofer
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

4.  Vancomycin-resistant enterococci colonization in patients with hematological malignancies: screening and its cost-effectiveness.

Authors:  Habip Gedik; Funda Şimşek; Arzu Kantürk; Taner Yıldırmak; Deniz Arıca; Demet Aydın; Osman Yokuş; Naciye Demirel
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

5.  Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.

Authors:  K L Kotloff; S S Wasserman; G A Losonsky; W Thomas; R Nichols; R Edelman; M Bridwell; T P Monath
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Is Clostridium difficile infection a risk factor for subsequent bloodstream infection?

Authors:  Robert J Ulrich; Kavitha Santhosh; Jill A Mogle; Vincent B Young; Krishna Rao
Journal:  Anaerobe       Date:  2017-06-29       Impact factor: 3.331

Review 7.  The intestinal microbiota and susceptibility to infection in immunocompromised patients.

Authors:  Ying Taur; Eric G Pamer
Journal:  Curr Opin Infect Dis       Date:  2013-08       Impact factor: 4.915

8.  Enterococci and Their Interactions with the Intestinal Microbiome.

Authors:  Krista Dubin; Eric G Pamer
Journal:  Microbiol Spectr       Date:  2014-11

9.  Vancomycin-resistant enterococcal bacteremia in a hematology unit: molecular epidemiology and analysis of clinical course.

Authors:  Jin-Hong Yoo; Dong-Gun Lee; Su Mi Choi; Jung-Hyun Choi; Wan-Shik Shin; Myungshin Kim; Dongeun Yong; Kyungwon Lee; Woo-Sung Min; Chun-Choo Kim
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

10.  Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes.

Authors:  Erik R Dubberke; Kimberlay A Reske; Anand Srivastava; Justin Sadhu; Robert Gatti; Rebecca M Young; Lauren C Rakes; Brian Dieckgraefe; John DiPersio; Victoria J Fraser
Journal:  Clin Transplant       Date:  2009-07-13       Impact factor: 2.863

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.